Literature DB >> 27702985

Cancer-specific mutations in p53 induce the translation of Δ160p53 promoting tumorigenesis.

Marco M Candeias1,2,3, Masatoshi Hagiwara2,4, Michiyuki Matsuda5,6.   

Abstract

Wild-type p53 functions as a tumour suppressor while mutant p53 possesses oncogenic potential. Until now it remains unclear how a single mutation can transform p53 into a functionally distinct gene harbouring a new set of original cellular roles. Here we show that the most common p53 cancer mutants express a larger number and higher levels of shorter p53 protein isoforms that are translated from the mutated full-length p53 mRNA. Cells expressing mutant p53 exhibit "gain-of-function" cancer phenotypes, such as enhanced cell survival, proliferation, invasion and adhesion, altered mammary tissue architecture and invasive cell structures. Interestingly, Δ160p53-overexpressing cells behave in a similar manner. In contrast, an exogenous or endogenous mutant p53 that fails to express Δ160p53 due to specific mutations or antisense knock-down loses pro-oncogenic potential. Our data support a model in which "gain-of-function" phenotypes induced by p53 mutations depend on the shorter p53 isoforms. As a conserved wild-type isoform, Δ160p53 has evolved during millions of years. We thus provide a rational explanation for the origin of the tumour-promoting functions of p53 mutations.
© 2016 The Authors.

Entities:  

Keywords:  GOFs; mutant p53; p53 isoforms; p53 mRNA; Δ160p53

Mesh:

Substances:

Year:  2016        PMID: 27702985      PMCID: PMC5090711          DOI: 10.15252/embr.201541956

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  33 in total

1.  Mutant p53 disrupts MCF-10A cell polarity in three-dimensional culture via epithelial-to-mesenchymal transitions.

Authors:  Yanhong Zhang; Wensheng Yan; Xinbin Chen
Journal:  J Biol Chem       Date:  2011-03-22       Impact factor: 5.157

2.  Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway.

Authors:  William A Freed-Pastor; Hideaki Mizuno; Xi Zhao; Anita Langerød; Sung-Hwan Moon; Ruth Rodriguez-Barrueco; Anthony Barsotti; Agustin Chicas; Wencheng Li; Alla Polotskaia; Mina J Bissell; Timothy F Osborne; Bin Tian; Scott W Lowe; Jose M Silva; Anne-Lise Børresen-Dale; Arnold J Levine; Jill Bargonetti; Carol Prives
Journal:  Cell       Date:  2012-01-20       Impact factor: 41.582

3.  The p53 isoform, Δ133p53α, stimulates angiogenesis and tumour progression.

Authors:  H Bernard; B Garmy-Susini; N Ainaoui; L Van Den Berghe; A Peurichard; S Javerzat; A Bikfalvi; D P Lane; J C Bourdon; A-C Prats
Journal:  Oncogene       Date:  2012-06-25       Impact factor: 9.867

4.  Cell-type, dose, and mutation-type specificity dictate mutant p53 functions in vivo.

Authors:  Ming Kei Lee; Wei Wei Teoh; Beng Hooi Phang; Wei Min Tong; Zhao Qi Wang; Kanaga Sabapathy
Journal:  Cancer Cell       Date:  2012-12-11       Impact factor: 31.743

5.  A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry.

Authors:  I Nicoletti; G Migliorati; M C Pagliacci; F Grignani; C Riccardi
Journal:  J Immunol Methods       Date:  1991-06-03       Impact factor: 2.303

Review 6.  When mutants gain new powers: news from the mutant p53 field.

Authors:  Ran Brosh; Varda Rotter
Journal:  Nat Rev Cancer       Date:  2009-08-20       Impact factor: 60.716

7.  30 years and a long way into p53 research.

Authors:  Pierre Hainaut; Klas G Wiman
Journal:  Lancet Oncol       Date:  2009-09       Impact factor: 41.316

Review 8.  Cytoplasmic functions of the tumour suppressor p53.

Authors:  Douglas R Green; Guido Kroemer
Journal:  Nature       Date:  2009-04-30       Impact factor: 49.962

9.  Mutant p53 drives invasion by promoting integrin recycling.

Authors:  Patricia A J Muller; Patrick T Caswell; Brendan Doyle; Marcin P Iwanicki; Ee H Tan; Saadia Karim; Natalia Lukashchuk; David A Gillespie; Robert L Ludwig; Pauline Gosselin; Anne Cromer; Joan S Brugge; Owen J Sansom; Jim C Norman; Karen H Vousden
Journal:  Cell       Date:  2009-12-24       Impact factor: 41.582

Review 10.  p53 mutations in cancer.

Authors:  Patricia A J Muller; Karen H Vousden
Journal:  Nat Cell Biol       Date:  2013-01       Impact factor: 28.824

View more
  24 in total

Review 1.  More than just scanning: the importance of cap-independent mRNA translation initiation for cellular stress response and cancer.

Authors:  Rafaela Lacerda; Juliane Menezes; Luísa Romão
Journal:  Cell Mol Life Sci       Date:  2016-12-02       Impact factor: 9.261

Review 2.  p53 Isoforms as Cancer Biomarkers and Therapeutic Targets.

Authors:  Liuqun Zhao; Suparna Sanyal
Journal:  Cancers (Basel)       Date:  2022-06-27       Impact factor: 6.575

Review 3.  p53 and Its Isoforms in Renal Cell Carcinoma-Do They Matter?

Authors:  Agata Swiatkowska
Journal:  Biomedicines       Date:  2022-06-06

Review 4.  Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells.

Authors:  Ugo Testa; Eleonora Petrucci; Luca Pasquini; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2018-02-01

Review 5.  Translation acrobatics: how cancer cells exploit alternate modes of translational initiation.

Authors:  Ashwin Sriram; Jonathan Bohlen; Aurelio A Teleman
Journal:  EMBO Rep       Date:  2018-09-17       Impact factor: 8.807

6.  Conformational stability and dynamics of the cancer-associated isoform Δ133p53β are modulated by p53 peptides and p53-specific DNA.

Authors:  Jiangtao Lei; Ruxi Qi; Yegen Tang; Wenning Wang; Guanghong Wei; Ruth Nussinov; Buyong Ma
Journal:  FASEB J       Date:  2018-12-12       Impact factor: 5.834

Review 7.  Pathogenesis and heterogeneity of ovarian cancer.

Authors:  Paul T Kroeger; Ronny Drapkin
Journal:  Curr Opin Obstet Gynecol       Date:  2017-02       Impact factor: 1.927

Review 8.  Putting p53 in Context.

Authors:  Edward R Kastenhuber; Scott W Lowe
Journal:  Cell       Date:  2017-09-07       Impact factor: 41.582

Review 9.  Mechanisms of TP53 Pathway Inactivation in Embryonic and Somatic Cells-Relevance for Understanding (Germ Cell) Tumorigenesis.

Authors:  Dennis M Timmerman; Tessa L Remmers; Sanne Hillenius; Leendert H J Looijenga
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

10.  Antitumor Effect of Lenvatinib Combined with Alisertib in Hepatocellular Carcinoma by Targeting the DNA Damage Pathway.

Authors:  Jianwen Hao; Qizhen Peng; Keruo Wang; Ge Yu; Yi Pan; Xiaoling Du; Na Hu; Xuening Zhang; Yu Qin; Huikai Li
Journal:  Biomed Res Int       Date:  2021-07-22       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.